Estudio diagnóstico de Parkinson

DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging Demonstrates Impact on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome

DaTscanTM (ioflupane 123I injection) US FDA-approved in January 2011, is the first FDA-approved

radiopharmaceutical indicated for striatal dopamine transporter visualization using single photon

emissionparkinsonian computed tomography (SPECT) brain imaging to assist in the evaluation of

adult patients with suspected parkinsonian syndromes (idiopathic Parkinson’s disease,

parasupranuclear palsy (PSP) and multiple system atrophy [MSA]). When utilized with SPECT imaging,

DaTscan, administered intravenously (IV) in a single dose, can detect the presence of functional

domaminergic neurons in the striatum of those patients with clinically uncertain parkinsonian

syndromes (PS). The product is designed to assist the clinician in the differential diagnosis of tremor

associated with PS vs. essential tremor (ET). DaTscan is not designed to differentiate among the

parkinsonian syndromes.